G01N 33/6866
Interferon
Official title: {Interferon}
G01N33/6866 (Interferon) appears on 224 US grants and 410 published applications in this corpus.
Search patents in G01N- Granted patents
- 224
- Published applications
- 410
- Assignees
- 254
- Inventors
- 822
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 3 | 0 |
| 1988 | 3 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 4 | 0 |
| 1999 | 4 | 0 |
| 2000 | 1 | 0 |
| 2001 | 5 | 0 |
| 2002 | 0 | 8 |
| 2003 | 2 | 14 |
| 2004 | 3 | 11 |
| 2005 | 0 | 7 |
| 2006 | 3 | 11 |
| 2007 | 1 | 5 |
| 2008 | 6 | 9 |
| 2009 | 7 | 9 |
| 2010 | 6 | 9 |
| 2011 | 9 | 11 |
| 2012 | 3 | 19 |
| 2013 | 9 | 23 |
| 2014 | 5 | 16 |
| 2015 | 8 | 28 |
| 2016 | 13 | 30 |
| 2017 | 17 | 25 |
| 2018 | 18 | 27 |
| 2019 | 16 | 19 |
| 2020 | 10 | 16 |
| 2021 | 10 | 19 |
| 2022 | 8 | 31 |
| 2023 | 7 | 17 |
| 2024 | 7 | 20 |
| 2025 | 12 | 15 |
| 2026 | 8 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- IFNβ as a pharmacodynamic marker in VSV-IFNβ-NIS oncolytic therapy6 Oct 2026US 12,754,182 B2Mayo Foundation for Medical Education and Research
- Anti-IFNAR1 antibodies19 May 2026US 12,630,639 B2Immunecent Biotechnology, Inc.
- Diagnostic blood test for sarcoidosis21 Apr 2026US 12,607,639 B2
- Method for diagnosing latent tuberculosis infection24 Mar 2026US 12,586,183 B2Oxford Immunotec Limited
- Methods and compositions for T-cell coculture potency assays and use with cell therapy products10 Mar 2026US 12,570,961 B2Iovance Biotherapeutics, Inc.
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Analyte quantification with bead and immuno qpcr-based elisa (biq-elisa)3 Sep 2026US 2026/0258475 A1
- Use of ifn-i activity as a biomarker for tlr inhibitor treatment6 Aug 2026US 2026/0227412 A1Merck Patent GmbH
- Methods of predicting and treating immunotherapy adverse events based on immune cell populations16 Jul 2026US 2026/0202406 A1Board of Regents, The University of Texas System
- Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex16 Jul 2026US 2026/0204354 A1Adaptimmune Limited
Most cited
By later US patents
- Patient classification703US 6,763,307 B2Bioseek, Inc. · 2004
- Antibodies to immunogenic peptides and their use to purify human fibroblast interferon67US 4,341,761 AE. I. Du Pont de Nemours and Company · 1982
- Freeze-dried composition containing enzyme-labeled anti-human interferon-.beta. antibody and enzyme immunoassay kit containing the composition59US 5,262,296 AToray Industries, Inc. · 1993
- Method for generating a subtracted cDNA library and uses of the generated library44US 5,643,761 AThe Trustees of Columbia University in the City of New York · 1997
- Protease activatable interferon alpha proprotein41US 8,399,219 B2CytomX Therapeutics, Inc. · 2013